Corey A. Carter
Experienced in Hypophosphatemia

Dr. Corey A. Carter

Hematology Oncology
8901 Wisconsin Ave, 
Bethesda, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Hypophosphatemia
8901 Wisconsin Ave, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Corey Carter is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Carter is rated as an Experienced provider by MediFind in the treatment of Hypophosphatemia. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Epithelial Tumor.

His clinical research consists of co-authoring 76 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hypophosphatemia.

Specialties
Hematology Oncology
Licenses
Internal Medicine in VA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

8901 Wisconsin Ave, Bethesda, MD 20889

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Study Phase: Phase 2
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)
A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)
Enrollment Status: Completed
Publish Date: November 18, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

76 Total Publications

Correlation of safety and efficacy of atezolizumab therapy across indications.
Correlation of safety and efficacy of atezolizumab therapy across indications.
Journal: Journal for immunotherapy of cancer
Published: October 18, 2024
Similar Doctors
Distinguished in Hypophosphatemia
Dr. Michael A. Auerbach
Hematology Oncology | Hematology | Oncology
Distinguished in Hypophosphatemia
Dr. Michael A. Auerbach
Hematology Oncology | Hematology | Oncology

Auerbach Hematology Oncology Associates P C

5233 King Ave, Suite 308, 
Baltimore, MD 
 (41.6 miles away)
410-780-4050
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Auerbach is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Auerbach is rated as a Distinguished provider by MediFind in the treatment of Hypophosphatemia. His top areas of expertise are Iron Deficiency Anemia, Anemia, Hypophosphatemia, and Childhood Iron Deficiency Anemia. Dr. Auerbach is currently accepting new patients.

Experienced in Hypophosphatemia
Dr. Gideon M. Blumenthal
Hematology Oncology
Experienced in Hypophosphatemia
Dr. Gideon M. Blumenthal
Hematology Oncology
8901 Wisconsin Ave, National Navy Medical Center Bldg. 8, Rm. 4152, 
Bethesda, MD 
 (0.1 miles away)
301-435-5868
Languages Spoken:
English

Gideon Blumenthal is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Blumenthal is rated as an Advanced provider by MediFind in the treatment of Hypophosphatemia. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Ruvalcaba Syndrome, Bannayan-Riley-Ruvalcaba Syndrome, and Tissue Biopsy.

Experienced in Hypophosphatemia
Dr. Richard Pazdur
Hematology Oncology
Experienced in Hypophosphatemia
Dr. Richard Pazdur
Hematology Oncology
10202 Addison Ct, 
Bethesda, MD 
 (2.5 miles away)
301-897-5828
Languages Spoken:
English

Richard Pazdur is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Pazdur is rated as an Advanced provider by MediFind in the treatment of Hypophosphatemia. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer, Tissue Biopsy, and Nephrectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carter's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile